CompletedPhase 4

The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia

China35 participantsStarted 2016-05

Plain-language summary

The purpose of this study is to compare the efficacy of cyclophosphamide plus dexamethasone combined with rituximab or bortezomib regimens in newly diagnosed Waldenström macroglobulinemia patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. aged \>=18 years
✓. diagnosed with LPL/WM
✓. untreated or mild treated without standard regimens,especially untreated with rituximab and/or bortezomib
✓. symptom patients
✓. with life-expectancy more than 3 months.

Exclusion criteria

✕. diagnosed with other malignancies outside B-NHL within one year(including active center neural system lymphoma)
✕. transformed lymphoma
✕. liver or renal function lesion unrelated to lymphoma
✕. serious complications such as uncontrolled diabetes,gastric ulcer or other serious angiocardiopathy determined by the physician
✕. HIV positive or active HBV infection or other uncontrolled systematic infection
✕. clinical central nervous dysfunction
✕. serious surgery within 30 days
✕. pregnancy or baby nursing period or un-contracepted child-bearing period woman; 9. allergy to the trail drugs.

What they're measuring

progress-free survival

Timeframe: up to 36 months

Trial details

NCT IDNCT02844322

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05

View on ClinicalTrials.gov More Waldenström Macroglobulinemia trials